… comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia  …

D Shortridge, C Carvalhaes… - Journal of …, 2021 - academic.oup.com
… The EUCAST susceptible breakpoint for meropenem/vaborbactam … meropenem component
and the inhibitory activity of vaborbactam, compared with the standard dose of meropenem

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized …

JM Cisneros, CM Rosso-Fernández, C Roca-Oporto… - Critical Care, 2019 - Springer
… infections caused by CR-GNB in 406 patients, 207 of whom had VAP [18]. … compare the
efficacy and safety of empirical treatment with intravenous colistin versus meropenem in patients

Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal …

S Razzazzadeh, IA Darazam, M Hajiesmaeili… - … Clinical Pharmacology, 2022 - Springer
… Acetaminophen was chosen as the internal standard due to structural and behavioral
similarities to meropenem. Initially, 950 μL of serum was added to 50 μL of acetaminophen (800 μg/…

… , and meropenem pharmacodynamic exposure against carbapenem-resistant Enterobacteriaceae in patients with bloodstream infection or hospital-acquired/ventilator …

JL Kuti, A Kim, DJ Cloutier, DP Nicolau - Infectious diseases and therapy, 2019 - Springer
compared with colistin for the treatment of patients with BSI and hospital-acquired/ventilator-associated
bacterial pneumonia … Combination therapy with either tigecycline or meropenem, …

Pharmacokinetic/pharmacodynamics-optimized antimicrobial therapy in patients with hospital-acquired pneumonia/ventilator-associated pneumonia

H Sulaiman, MH Abdul-Aziz… - Seminars in Respiratory …, 2017 - thieme-connect.com
meropenem reached more than 100% penetration following a single dose of 1 g meropenem
This was shown in an individual patient level meta-analysis which specifically compared CI …

Pharmacokinetic/Pharmacodynamic Optimization of Hospital-Acquired and Ventilator-Associated Pneumonia: Challenges and Strategies

YP Abouelhassan, D Nicolau - Seminars in Respiratory and …, 2022 - thieme-connect.com
… (with 1,051 patients) of nosocomial pneumonia were compared between intermittent infusion
… variability of penetration in 39 VAP patients treated with meropenem 2 g IV infusion over 3 …

… monotherapy and colistin–meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug …

MFA Abdelsalam, MS Abdalla… - Journal of global …, 2018 - Elsevier
… recent study was published comparing colistin alone versus colistin plus meropenem for
the … including hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), …

Clinical effectiveness of a high dose versus the standard dose of meropenem in ventilator-associated pneumonia caused by multidrugresistant bacteria: a randomized …

M Monajati, S Ala, M Aliyali… - … Current Drug Targets …, 2021 - ingentaconnect.com
… and the pharmacokinetic parameter of not critically ill patients. We compared the efficacy
of high versus standard dose of meropenem in ventilator-associated pneumonia (VAP). …

Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa

N Farrington, V Dubey, A Johnson, I Horner… - Mbio, 2024 - Am Soc Microbiol
differences in the protein binding of meropenem in humans and rabbits. A 24-hour delay in
initial treatment was used for all patients… in patients with ventilator-associated pneumonia. Am …

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia

MA Ammar, W Abdalla - Saudi journal of anaesthesia, 2018 - journals.lww.com
… was to compare the efficacy and safety of extended infusion of meropenem and nebulized
… new dosing strategies to optimize the pharmacodynamics of the existing antimicrobials. This …